Terms: = Endocrine gland cancer AND PML, TRIM19, 5371, ENSG00000140464, MYL, PP8675, RNF71 AND Prognosis
4 results:
1. Systems biomarkers for papillary thyroid cancer prognosis and treatment through multi-omics networks.
Gulfidan G; Soylu M; Demirel D; Erdonmez HBC; Beklen H; Ozbek Sarica P; Arga KY; Turanli B
Arch Biochem Biophys; 2022 Jan; 715():109085. PubMed ID: 34800440
[TBL] [Abstract] [Full Text] [Related]
2. pml hyposumoylation is responsible for the resistance of pancreatic cancer.
Swayden M; Alzeeb G; Masoud R; Berthois Y; Audebert S; Camoin L; Hannouche L; Vachon H; Gayet O; Bigonnet M; Roques J; Silvy F; Carrier A; Dusetti N; Iovanna JL; Soubeyran P
FASEB J; 2019 Nov; 33(11):12447-12463. PubMed ID: 31557059
[TBL] [Abstract] [Full Text] [Related]
3. May increased CA125 in borderline ovarian tumor be indicative of a poor prognosis? A case report.
Anastasi E; Porpora MG; Pecorella I; Bernardo S; Frati L; Benedetti Panici P; Manganaro L
Tumour Biol; 2014 Jul; 35(7):6969-71. PubMed ID: 24740561
[TBL] [Abstract] [Full Text] [Related]
4. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.
Marinoni I; Kurrer AS; Vassella E; Dettmer M; Rudolph T; Banz V; Hunger F; Pasquinelli S; Speel EJ; Perren A
Gastroenterology; 2014 Feb; 146(2):453-60.e5. PubMed ID: 24148618
[TBL] [Abstract] [Full Text] [Related]
